TTR rs113058577 (V122I): Risk and Amyloid Cardiomyopathy
The rs113058577 variant (frequently referenced in clinical literature as V122I or p.Val142Ile) is a missense alteration in the TTR gene. It leads to the production of an unstable transthyretin protein that can aggregate into amyloid fibrils, accumulating in organs such as the heart and peripheral nerves. Carrying this variant is statistically linked to hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) and related conditions, particularly in individuals of African ancestry.
What each genotype means
Typical TTR gene profile
This is the most common genotype for the TTR gene, representing the wild-type sequence. Individuals with this genotype do not carry the specific V122I (p.Val142Ile) variant associated with hereditary transthyretin amyloid cardiomyopathy.
This is the predominant genotype in all human populations.
Increased risk for amyloidosis
This genotype indicates you carry one copy of the V122I (p.Val142Ile) variant, which is associated with an increased risk of developing hereditary transthyretin amyloid cardiomyopathy (ATTR-CM). Research indicates that while this variant is linked to late-onset heart disease, clinical penetrance varies, meaning not all carriers will develop symptomatic heart failure. Please discuss this result with your clinician to determine if cardiac screening or monitoring is appropriate for your health profile.
This genotype is carried by approximately 3-4% of individuals of African ancestry and is rare in other populations.
High risk for amyloidosis
This genotype indicates you carry two copies of the V122I (p.Val142Ile) variant. This variant is known to destabilize the transthyretin protein, potentially leading to amyloid fibril deposition in the heart. Clinical research suggests this is a pathogenic variant associated with hereditary transthyretin amyloid cardiomyopathy, and you should consult with a cardiologist or genetic counselor to discuss your cardiovascular health.
This genotype is very rare, occurring primarily in individuals of African ancestry.
Genetic Architecture and Variant Nomenclature
The rs113058577 variant represents a single nucleotide transition located within exon 5 of the TTR gene on chromosome 18q12.1. In standard genomic coordinate systems, it is designated as c.424G>A, resulting in the substitution of valine with isoleucine. In contemporary protein nomenclature adhering to HGVS standards, this is termed p.Val142Ile to account for the inclusion of the 20-amino-acid signal peptide. However, historic and clinical cardiology literature often references this exact change as V122I based on the numbering of the mature secreted protein. In dbSNP records, this loci is closely related to cataloged identifier rs76992529. The alteration replaces a conserved, hydrophobic amino acid, thereby destabilizing the native homotetrameric quaternary structure of the circulating transthyretin complex.
Biological Function of the TTR Gene
The TTR gene provides instructions for producing transthyretin, a serum transport protein synthesized predominantly by the liver, as well as the choroid plexus of the brain and the retinal pigment epithelium. Transthyretin normally circulates as a stable four-subunit tetramer tasked with carrying thyroxine (vitamin hormone T4) and retinol (vitamin A, via retinol-binding protein) throughout the bloodstream. When a missense mutation like V122I is present, the rate-limiting dissociation of the tetramer into monomeric intermediates is accelerated. These misfolded monomers subsequently self-assemble into insoluble, cross-beta sheet amyloid fibrils. As these fibrils aggregate within the extracellular matrix of heart muscle tissue, they disrupt mechanical function and structural compliance, ultimately impeding cardiac relaxation and filling.
Clinical Associations and Strength of Evidence
Extensive biomedical research published in journals such as the [New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa1404852) and the [Journal of the American College of Cardiology](https://www.jacc.org/doi/10.1016/j.jacc.2020.04.074) confirms that rs113058577 is a major causal factor in late-onset hereditary transthyretin amyloid cardiomyopathy (ATTR-CM). Affected carriers frequently experience late-onset congestive heart failure, restrictive cardiomyopathy, and conduction abnormalities, typically developing in their 60s, 70s, or 80s. Emerging multi-biobank investigations published in [Scientific Reports](https://www.nature.com/articles/s41598-021-91113-6) also demonstrate robust associations with polyneuropathy and preceding carpal tunnel syndrome, the latter often manifesting 5 to 10 years before cardiac diagnosis. Despite the strong association, clinical penetrance is incomplete, meaning not all carriers will develop symptomatic amyloidosis during their lifetime.
Ancestry and Population Frequency
Epidemiological evaluations, including multi-cohort analyses published in [Amyloid](https://www.tandfonline.com/doi/full/10.3109/13506129.2015.1051219) and [Frontiers in Cardiovascular Medicine](https://pmc.ncbi.nlm.nih.gov/articles/PMC9360589/), show that the V122I allele is primarily carried by individuals of West African ancestry. Approximately 3% to 4% of African American individuals carry at least one copy of the variant (an allele frequency of roughly 0.017 to 0.020). By contrast, it is exceptionally rare among populations of European, East Asian, and Indigenous American ancestry without recent African admixture. Because this variant is carried by an estimated 1.5 to 1.6 million individuals in the United States alone, yet has historically faced low clinical detection rates, researchers highlight it as an important target for reducing underdiagnosis and health disparities in cardiovascular care.
Navigating Genetic Results Responsibly
Discovering an rs113058577 risk allele on a consumer or research genetic test does not constitute a clinical diagnosis of cardiac amyloidosis. Because clinical penetrance is variable, possessing the variant indicates potential predisposition rather than guaranteed illness. Clinical evaluations generally require specialized noninvasive screening—such as technetium-99m-pyrophosphate (PYP) nuclear scintigraphy, cardiac MRI, biomarker evaluation, or echocardiography—guided by a cardiologist or medical geneticist. Any discussion regarding medical diagnostics, cardiac symptom monitoring, or pharmacotherapy targeting transthyretin tetramer stabilization should always be conducted in consultation with a qualified physician or genetic counselor.
How common is this variant?
The variant is carried by approximately 3% to 4% of individuals of African American and West African descent, with an allele frequency of roughly 0.017 to 0.020, while remaining extremely rare in other global ancestries.
Frequently asked questions
What is the difference between V122I and p.Val142Ile?
They are two names for the exact same genetic change in the TTR gene. V122I is the historical name derived from the mature, processed protein, whereas p.Val142Ile is the modern HGVS nomenclature counting the 20-amino-acid signal peptide sequence.
Does carrying the rs113058577 variant mean I will definitely develop heart failure?
No. The variant displays incomplete penetrance, meaning that while it increases your statistical risk, a significant proportion of carriers live without ever developing clinical cardiac amyloidosis. Regular monitoring with a healthcare professional can help track cardiac health as one ages.
Why is carpal tunnel syndrome often mentioned with this mutation?
Insoluble transthyretin amyloid fibrils frequently accumulate in musculoskeletal soft tissues long before significant cardiac symptoms emerge. Bilateral carpal tunnel syndrome often precedes the clinical diagnosis of cardiac amyloidosis by 5 to 10 years, serving as a recognized early warning sign.
What should I do if my genetic test shows I am a carrier?
Share your genetic findings with your primary care provider or a cardiologist for clinical context and confirmation. They can assess your overall cardiovascular health and determine whether baseline evaluations, such as an echocardiogram or nuclear imaging, are warranted.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs113058577?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TTR
Prevalent founder variant (p.Val142Ile) predisposing individuals of African ancestry to late-onset hereditary transthyretin amyloid cardiomyopathy.
Causes the classic p.Val50Met (historically Val30Met) pathogenic substitution responsible for familial amyloid polyneuropathy and hereditary transthyretin amyloidosis (ATTR).
Transthyretin missense variant p.Val142Ile (V122I) associated with hereditary transthyretin amyloid cardiomyopathy.
Pathogenic missense variant (commonly designated Val30Met or p.Val50Met) associated with hereditary transthyretin-mediated amyloidosis.
Causes hereditary transthyretin amyloidosis (V122I), common in African Americans.